Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03433703 · ClinicalTrials.gov registry record · Phase 2
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
A Phase 2 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03433703 is a Phase 2 study that was terminated before completion, run by Eisai. The registered enrollment target is 8 participants.
The verdict
NCT03433703, a Phase 2 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and tolerability of subsequent systemic treatment of physician's choice (TPC) following the first-line lenvatinib treatment in unresectable hepatocellular carcinoma (uHCC) participants.
Interventions
- DRUG Lenvatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2019-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03433703
The ClinicalTrials.gov registry entry for NCT03433703 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenvatinib is the first listed.
NCT03433703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03433703 about?
NCT03433703 is a clinical study titled "Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)". The primary objective of this study is to assess the safety and tolerability of subsequent systemic treatment of physician's choice (TPC) following the first-line lenvatinib treatment in unresectable hepatocellular carcinoma (uHCC) participants.
What is the current status of trial NCT03433703?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2018-04-26. Estimated completion is 2019-01-07.
What interventions are being tested in trial NCT03433703?
The interventions under investigation include: Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT03433703?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.